Melanotan II (MT-2): Uses, Risks & Legal Status (2026)

Editorially reviewed · Last updated June 2026 · This article is educational and is not medical advice. Talk to a licensed clinician before using any peptide.

What is Melanotan II?

Melanotan II is a lab-made peptide that mimics α-melanocyte-stimulating hormone (α-MSH). It binds non-selectively across the melanocortin receptors (MC1R–MC5R), which is why its effects spill well beyond tanning into the cardiovascular, sexual, gastrointestinal, and nervous systems.

Activating MC1R drives melanocytes to produce more eumelanin, darkening the skin with relatively little sun exposure — the effect that earned it the "Barbie drug" nickname. Activating the other melanocortin receptors is what produces the spontaneous erections, nausea, and appetite suppression people also report.

An important distinction: Melanotan II is not the same as the FDA-approved drug it's often confused with. Afamelanotide ("Melanotan I," brand name Scenesse) is an approved, implanted drug for a rare light-sensitivity disorder. Bremelanotide (Vyleesi) is an approved drug for low sexual desire in some women — see our PT-141 page for how that differs from grey-market listings. Melanotan II itself has never been approved for anything, and the injectable powder sold online is unregulated and untested.

What people use Melanotan II for

People most commonly report using it for:

• Sunless or accelerated tanning (the primary driver)
• Libido and erectile effects (a melanocortin side effect, not an approved use)
• Appetite suppression / weight effects (an off-target effect, not a validated use)

Separate reported use from proven use carefully. The approved, studied melanocortin drugs are different molecules with controlled doses and oversight. The tanning, libido, and appetite effects people chase with MT-2 come bundled with the documented toxicity below — there is no version of this product that delivers the upside without the unregulated risk.

Melanotan II "dosing": why this page won't give you a protocol

For the recovery peptides on this site, we publish commonly-reported ranges with heavy disclaimers. For Melanotan II we deliberately do not, and the reason is concrete:

• Community use centers on very small amounts — on the order of a milligram or less to start, because the margin to harm is thin.
• In a published case report, a 6 mg dose — only about six times a typical starting amount — caused systemic toxicity, rhabdomyolysis (muscle breakdown), kidney dysfunction, and a three-day ICU stay. Another documented case produced priapism after a roughly 2 mg subcutaneous dose.
• The product is sold as a powder users reconstitute and measure themselves, and dosing errors are repeatedly cited in the medical literature as a leading cause of MT-2 toxicity.

So the honest, useful thing to tell a reader is not "inject X on day one." It's that the gap between a "normal" dose and a hospitalization-level dose is small, the measurement is error-prone, and there is no clinically established safe dose for self-administration. Anyone who has decided to use it anyway should do so only under medical supervision — not from a forum schedule.

How it's reconstituted (and why that's part of the danger)

MT-2 ships as a freeze-dried powder mixed with bacteriostatic water before injection. The number of insulin-syringe "units" you draw depends entirely on how much water you add — and with MT-2, a miscalculation isn't a wasted dose, it's the documented pathway to rhabdomyolysis and ER visits. Use our peptide calculator only if you are documenting a stated mass in a vial; it does not make self-dosing safe. This reconstitution-math fragility is exactly why self-dosing this particular peptide is so risky.

Melanotan II side effects and safety

This is the section that sets MT-2 apart. Its risks are not theoretical — they come from peer-reviewed case reports and poison-center data:

Commonly reported:

• Nausea and vomiting (very common, often in the hours after injection)
• Facial flushing, acne, appetite suppression
• Spontaneous erections in men
• Darkening of existing moles and freckles, and new pigmented spots

Documented serious harms:

• Priapism — prolonged, painful erection that is a urological emergency; published cases have required injections and even surgical intervention to resolve.
• Rhabdomyolysis and acute kidney injury — muscle breakdown that can damage the kidneys; a documented case involved a CPK in the tens of thousands and ICU care.
• Sympathomimetic toxicity — hypertension, rapid heart rate, agitation, sweating.

The mole and melanoma question:

MT-2 reliably darkens moles and can stimulate new and atypical (dysplastic) nevi, and there are case reports of melanoma in users. Whether MT-2 causesmelanoma is genuinely unsettled — many reported cases coincided with heavy UV/sunbed exposure, which is its own strong risk factor. But there's a second, less-debated danger: by darkening and changing moles, MT-2 can mask the early visual signs of melanoma, making a dangerous lesion harder to catch. That alone is a serious reason for caution.

Stop and seek emergency care for: an erection lasting more than 4 hours; severe muscle pain or dark/cola-colored urine (possible rhabdomyolysis); chest pain, severe headache, or very high blood pressure; or any mole that is changing, growing, bleeding, or asymmetric.

Is Melanotan II legal in 2026?

Melanotan II's legal status is more restrictive than the other peptides on this site, and it is moving in a different direction:

• It is not approved by the FDA — or any comparable regulator — for any use, and it is illegal to sell for human use in the US, UK, Australia, and New Zealand.
• It is sold only as a "Research Use Only" / "not for human consumption" product — a liability shield for the seller, not a safety clearance.
• Australia has scheduled it as a prohibited substance (Schedule 9) as of early 2026, meaning possession without a research licence can carry criminal penalties — a much harder line than the gray-market status of recovery peptides. See the TGA's melanotan advisory.
• The FDA has a criminal-enforcement history here: the Melanocorp / Manookian case ended in a guilty plea and debarment, and FDA enforcement against online MT-2 sellers has continued into 2026.
• On the 2026 compounding shake-up: Melanotan II was removed from FDA "Category 2" in April 2026 alongside roughly a dozen peptides — but, unlike BPC-157, TB-500, and MOTS-C, it is widely expected to remain restricted rather than become legally compoundable, and it is not among the peptides up for the July 23–24, 2026 PCAC review. Removal from Category 2 is not approval and not a safety clearance.

Bottom line: using it makes you personally responsible for an unapproved product with documented harms, and in some jurisdictions possession itself is now a criminal matter.

How to evaluate sourcing (and why it matters even more here)

If someone uses it despite all of the above, unregulated sourcing compounds every risk already listed:

• A recent, batch-specific Certificate of Analysis (COA) with HPLC purity (ideally ≥98%) and mass-spec identity confirmation.
• Independent third-party testing, not just the vendor's in-house lab.
• Sterile, sealed vials and clear storage guidance.
• Realistic claims — any vendor calling MT-2 "safe," "FDA-approved," or a "clinically proven" tanning product is lying, and that's a reason to walk away entirely.

With MT-2 specifically, contamination or mislabeling stacks directly on top of a peptide that already causes documented organ toxicity at the wrong dose.

Who should not use Melanotan II

Realistically this list is broad, because the risk profile is broad:

• Anyone with a personal or family history of melanoma, skin cancer, or atypical/dysplastic moles
• Anyone with high blood pressure, heart disease, or kidney problems
• Anyone pregnant or breastfeeding
• Anyone who tans heavily or uses sunbeds (compounds the melanoma concern)
• Anyone who can't get medical oversight or verify their source
• Minors
• Residents of jurisdictions where possession is criminalized

References

• Nelson et al. — Melanotan II injection resulting in systemic toxicity and rhabdomyolysis, Clinical Toxicology
• Mallory et al. — Melanotan tanning injection: a rare cause of priapism, Journal of Sexual Medicine
• Bonchev — Changes in oral mucosa associated with Melanotan II injections: a case report, Life
• FDA — Notice of Opportunity for Hearing, Melanocorp/Manookian (criminal enforcement history)
• LegitScript — Emerging Threat: Melanotan, Repackaging, and Online Sales
• FDA — Category 2 bulk-substance update, April 2026; PCAC July 23–24, 2026 meeting scope